1-9 of 9
Shimrit Ringelstein
Close
Sort by
Journal Articles

CNS Prophylaxis in Diffuse Large B-Cell Lymphoma: A Common Toxic Clinical Practice Based on Abundant Opinion, Despite Evidence Suggesting Futility

Ofrat Beyar Katz, Shimrit Ringelstein-Harlev, Jacob M. Rowe
Journal: Blood
Blood (2023) 142 (Supplement 1): 7260.
https://doi.org/10.1182/blood-2023-178320
Published: 2023
Journal Articles

The ELN 2022 Risk Stratification Has No Impact on the Dismal Prognosis of Patients with Acute Undifferentiated Leukemia

Baher Krayem, Tsila Zuckerman, Avraham Frisch, Ilana Slouzkey, Tehila Azoulay, Michal Karmona, Liran I. Shlush, Nathali Kaushansky, Noa Chapal-Ilani, Shimrit Ringelstein-Harlev
Journal: Blood
Blood (2023) 142 (Supplement 1): 4221.
https://doi.org/10.1182/blood-2023-188592
Published: 2023
Journal Articles

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2

Eldad J Dann, Tsofia Inbar, Tania Mashiach, Jamela Eisa, Shimrit Ringelstein Harlev, Netanel A Horowitz
Journal: Blood
Blood (2021) 138 (Supplement 1): 2458.
https://doi.org/10.1182/blood-2021-149379
Published: 2021
Journal Articles

A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study

Ron Ram, Sigal Grisariu, Liat Shargian-Alon, Dana Yehudai-Ofir, Irit Avivi, Orit Gutfeld, Polina Stepensky, Tsila Zuckerman, Moshe Yeshurun, Odelia Amit, Batia Avni, Ronit Gurion, Yael Bar-On, Ofrat Beyar-Katz, Ronit Gold, Shimrit Ringelstein, Itai Levi, Tzvi Porges, Chava Perry
Journal: Blood
Blood (2021) 138 (Supplement 1): 1733.
https://doi.org/10.1182/blood-2021-151085
Published: 2021
Journal Articles

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Yafit Segman, MD, Elena Ribakovsky, MD, Abraham Avigdor, MD, Vladimir Vainstein, MD, Neta Goldschmidt, MD, Shimrit Ringelstein Harlev, MD, Odit Gutwein, Uri Abadi, MD, Anatoly Nemets, MD, Orit Sofer, Najib Dally, MD, Kalman Filanovsky, MD, Merav Leiba, MD, Nadav Sarid, MD, Noam Benyamini, MD, Yair Herishanu, MD, Ron Ram, MD, Chava Perry, MD PhD, Irit Avivi
Journal: Blood
Blood (2019) 134 (Supplement_1): 5321.
https://doi.org/10.1182/blood-2019-124164
Published: 2019
Journal Articles

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Odelia Amit, MD, Yael Bar-On, MD, Irit Avivi, Tsila Zuckerman, MD, Galit Perets, MD, Israel Henig, MD, Itai Levi, MD, Dana Yehudai-Ofir, MD, Shimrit Ringelstein Harlev, MD, Ron Ram, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5654.
https://doi.org/10.1182/blood-2019-128248
Published: 2019
Journal Articles

TLR9-Regulated IL10 Mediates Immune Inhibitory Activity of Chronic Lymphocytic Leukemia B-Cells

Shimrit Ringelstein-Harlev, MD PhD, Mona Fanadka, BSc, Netanel A. Horowitz, MD, Irit Avivi, MD, Tami Katz, PhD
Journal: Blood
Blood (2016) 128 (22): 4377.
https://doi.org/10.1182/blood.V128.22.4377.4377
Published: 2016
Journal Articles

Chronic Lymphocytic Leukemia Cells Acquire a Regulatory B-Cell Phenotype Modified By PD1 Signaling

Shimrit Ringelstein-Harlev, MD, Irit Avivi, MD, Shoham Shivtiel-Arad, PhD, Tami Katz, PhD
Journal: Blood
Blood (2014) 124 (21): 3319.
https://doi.org/10.1182/blood.V124.21.3319.3319
Published: 2014
Journal Articles

Chronic Lymphocytic Leukemia Cells Exhibit Inhibitory Properties of Regulatory B Cells

Shimrit Ringelstein-Harlev, MD, Irit Avivi, MD, Lina Bisharat, Tamar Katz, Ph.D
Journal: Blood
Blood (2012) 120 (21): 3874.
https://doi.org/10.1182/blood.V120.21.3874.3874
Published: 2012